Illumina co-founder Mark Chee moves from the genome to the proteome with upstart Encodia
When Mark Chee co-founded Illumina in 1998, the genomics field was just heating up. It had been three years since the first bacterium genome was sequenced, but the Human Genome Project was still years away from completion. That space has since erupted, and now Chee is on to what researchers think is the next big thing: proteomics.
Chee and fellow Illumina veteran Kevin Gunderson co-founded protein sequencing-focused Encodia back in 2015. After keeping quiet for the last few years, the upstart broke the silence on Wednesday to spread the word of its $75 million Series C round, led by Northpond Ventures and Deerfield Management. The funds will be used to commercialize Encodia’s patented protein analysis platform, dubbed ProteoCode.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
